StockNews.AI
VEEV
StockNews.AI
76 days

Veeva and Sarah Cannon Research Institute Form Strategic Collaboration to Advance Oncology Clinical Trials

1. Veeva partners with SCRI to enhance oncology trial efficiency. 2. SCRI adopts Veeva Clinical Platform for streamlined data flow across trials. 3. Collaboration aims to deliver groundbreaking therapies faster and cost-effectively. 4. Veeva's platform standardizes operations for trial processes and information sharing. 5. SCRI has a strong track record with over 850 first-in-human trials conducted.

7m saved
Insight
Article

FAQ

Why Bullish?

Veeva's partnership with a leading oncology organization enhances credibility and potential revenue. Historical collaborations in pharma have often resulted in stock price increases due to increased operational efficiency and revenue projections.

How important is it?

The partnership significantly boosts Veeva's standing in the oncology sector, which could lead to more collaborations and greater market share. This is crucial as the demand for digital solutions in clinical trials is increasing.

Why Long Term?

The collaboration is likely to yield long-term benefits as streamlined clinical trials may produce more new therapies, driving revenue growth. Similar partnerships in the past led to sustained increases in stock prices over multiple quarters.

Related Companies

BMYJNJMRNAPFE
Leading oncology research organization adopts Veeva Clinical Platform to enhance study delivery , /PRNewswire/ -- Veeva Systems (NYSE: VEEV) and Sarah Cannon Research Institute (SCRI) today announced a strategic collaboration to drive speed and efficiency in oncology clinical trials across SCRI's more than 200 research site locations. SCRI is adopting Veeva Clinical Platform to unify its contract research organization (CRO) and site management organization (SMO) on a single platform for seamless data flow across clinical teams and research sites. "We are thrilled to advance our clinical trials by integrating Veeva Clinical Platform into our digital toolkit," said SCRI chief information and digital officer Yazhene Krishnaraj. "This strategic collaboration empowers our clinical teams to deliver groundbreaking therapies to patients with enhanced precision and speed." Veeva Clinical Platform will enable SCRI to simplify and standardize trial processes and information flow, improving how investigators and clinical teams work together and share data. With a connected foundation for clinical research, SCRI will be able to automate key processes and provide a streamlined experience for its sites. "We're excited to work closely with SCRI to drive innovation in oncology research," said Jim Reilly, president of Veeva Development Cloud. "In a first-of-a-kind partnership, Veeva Clinical Platform will serve as SCRI's clinical trial foundation for its CRO and SMO. By standardizing operations on one platform, we can support SCRI in delivering faster and more cost-effective trials." About Veeva Clinical PlatformVeeva Clinical Platform is a complete and connected platform across clinical operations and data applications. This end-to-end platform includes CTMS, EDC, clinical workbench (CDB), RTSM, eCOA, eTMF, Site Connect, Study Training, and more. Connected products streamline clinical trials from study start-up to close and automate a connected data flow. To learn more about Veeva Clinical Platform, visit veeva.com/VeevaClinicalPlatform. About Sarah Cannon Research InstituteSarah Cannon Research Institute (SCRI) is one of the world's leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI's research network brings together more than 1,300 physicians who are enrolling patients to clinical trials at over 200 locations in more than 20 states across the U.S. Visit SCRI.com to learn more. About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com. Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva's strategic collaboration with SCRI and the expected results or benefits from such collaboration. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at sec.gov. SOURCE Veeva Systems WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News